0001708138-20-000012.txt : 20200226
0001708138-20-000012.hdr.sgml : 20200226
20200226181457
ACCESSION NUMBER: 0001708138-20-000012
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200224
FILED AS OF DATE: 20200226
DATE AS OF CHANGE: 20200226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Landry Robert E
CENTRAL INDEX KEY: 0001585160
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 20657663
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2020-02-24
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001585160
Landry Robert E
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
0
1
0
0
EVP Finance CFO
Common Stock
2020-02-24
4
M
0
1000
272.7
A
25973
D
Common Stock
2020-02-24
4
F
0
786
406.59
D
25187
D
Common Stock
2020-02-25
4
M
0
1000
272.7
A
26187
D
Common Stock
2020-02-25
4
F
0
800
447.3
D
25387
D
Common Stock
2020-02-25
4
S
0
10
438.0
D
25377
D
Common Stock
2020-02-25
4
S
0
12
444.03
D
25365
D
Common Stock
2020-02-25
4
S
0
11
445.35
D
25354
D
Common Stock
2020-02-25
4
S
0
37
447.11
D
25317
D
Common Stock
2020-02-25
4
S
0
18
448.54
D
25299
D
Common Stock
2020-02-25
4
S
0
54
449.5
D
25245
D
Common Stock
2020-02-25
4
S
0
35
450.8
D
25210
D
Common Stock
2020-02-25
4
S
0
16
453.6
D
25194
D
Common Stock
2020-02-25
4
S
0
4
454.67
D
25190
D
Common Stock
2020-02-25
4
S
0
17
455.13
D
25173
D
Common Stock
2020-02-26
4
S
0
10
452.04
D
25163
D
Common Stock
2020-02-26
4
S
0
44
453.36
D
25119
D
Common Stock
2020-02-26
4
S
0
18
454.85
D
25101
D
Common Stock
2020-02-26
4
S
0
32
455.37
D
25069
D
Common Stock
2020-02-26
4
S
0
10
456.67
D
25059
D
Common Stock
2020-02-26
4
S
0
25
457.23
D
25034
D
Common Stock
2020-02-26
4
S
0
27
458.35
D
25007
D
Common Stock
2020-02-26
4
S
0
34
460.05
D
24973
D
Common Stock
172
I
By 401(k) Plan
Non-Qualified Stock Option (right to buy)
272.7
2020-02-24
4
M
0
1000
0.0
D
2023-09-09
Common Stock
1000
55500
D
Non-Qualified Stock Option (right to buy)
272.7
2020-02-25
4
M
0
1000
0.0
D
2023-09-09
Common Stock
1000
54500
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 37 shares of Company stock on February 25, 2020 at prices ranging from $447.00 to $447.24. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2020 at each separate price.
Represents volume-weighted average price of sales of 54 shares of Company stock on February 25, 2020 at prices ranging from $449.01 to $449.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2020 at each separate price.
Represents volume-weighted average price of sales of 35 shares of Company stock on February 25, 2020 at prices ranging from $450.70 to $450.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 25, 2020 at each separate price.
Represents volume-weighted average price of sales of 44 shares of Company stock on February 26, 2020 at prices ranging from $453.04 to $453.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
Represents volume-weighted average price of sales of 32 shares of Company stock on February 26, 2020 at prices ranging from $455.24 to $455.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
Represents volume-weighted average price of sales of 25 shares of Company stock on February 26, 2020 at prices ranging from $457.10 to $457.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
Represents volume-weighted average price of sales of 27 shares of Company stock on February 26, 2020 at prices ranging from $458.11 to $458.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
Represents volume-weighted average price of sales of 34 shares of Company stock on February 26, 2020 at prices ranging from $460.03 to $460.07. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 26, 2020 at each separate price.
The stock option award vests in four equal annual installments, commencing one year after the date of grant.
/s/**Robert E. Landry
2020-02-26